Indrabi 2013.

Methods	Open‐label randomised clinical trial.
Participants	Criteria used to define hepatorenal syndrome: no description. Type 1 hepatorenal syndrome = 60 participants included. Demographics: no description.
Interventions	Terlipressin: Administration form: intravenous. Other vasoactive drug:noradrenaline. Administration form: intravenous. Cointervention: both arms treated with albumin. Dose not reported.
Outcomes	No description. Data on reversal of hepatorenal syndrome and mortality available.
Treatment duration	Treatment duration: no description. Follow‐up: 90 days or death.
Country of origin	India.
Inclusion period	No description.
Notes	Full paper.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No description.
Allocation concealment (selection bias)	Unclear risk	No description.
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding of participants or personnel.
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding of outcome assessment.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No description.
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes described and reported. No differences between trial registration/protocol and published paper identified.
For‐profit bias	Unclear risk	No description.
Overall risk of bias (non‐mortality outcomes)	High risk
Overall risk of bias (mortality)	High risk